Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
Jessica Gillen1, Debra Richardson1, Kathleen Moore2
1The University of Oklahoma Stephenson Cancer Center, 800 NE 10th Street, Oklahoma City, OK, 73104, USA.
Purpose Of Review:
The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition.
Recent Findings:
Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.
Insights
Tie2-angiopoietin inhibition shows promise in reducing tumor growth and metastasis in preclinical studies. Clinical trial results are mixed, warranting further investigation for optimal use in cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Tie2-angiopoietin system is crucial for vascular development and homeostasis.
- Dysregulation of this pathway contributes to tumor angiogenesis, growth, and metastasis.
- Targeting Tie2 offers a potential therapeutic strategy for various cancers.
Purpose of the Study:
- To review the current understanding of the Tie2-angiopoietin system in cancer.
- To discuss preclinical and clinical data on Tie2-angiopoietin inhibition therapies.
- To evaluate the efficacy and future potential of Tie2 inhibitors in oncology.
Main Methods:
- Comprehensive literature review of preclinical models and clinical trials.
- Analysis of data from studies evaluating Tie2-angiopoietin inhibitors.
- Focus on tumor growth, metastasis, and therapeutic responses.
Main Results:
- Tie2 inhibition demonstrated significant efficacy in preclinical cancer models, reducing tumor burden and metastasis.
- Clinical trials with inhibitors like trebananib, rebastanib, and MEDI3617 have yielded mixed results.
- Ongoing investigations explore Tie2-angiopoietin inhibitors in recurrent or metastatic breast and renal cell carcinomas.
Conclusions:
- The Tie2-angiopoietin pathway remains a promising target for cancer therapy.
- Further clinical evaluation is necessary to determine the optimal utility of Tie2 inhibitors.
- Understanding the nuances of Tie2 inhibition in human trials is critical for advancing cancer treatment.
Related Concept Videos
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Piaget's Stage 1 of Cognitive Development
Exploration...
Piaget's Stage 2 of Cognitive Development
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Overview
The nitrous acid is unstable. Hence, it is formed in situ from a solution of sodium nitrite and cold aqueous acids such as hydrochloric or sulfuric acid. In an acidic solution, the –OH group of nitrous acid undergoes protonation to give oxonium ion, followed by...
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Mechanism


